Monday September 01, 2014




Home »  News »  Health

Ontario will cover cost of Kalydeco for people with rare form of cystic fibrosis

OTTAWA - Ontario Premier Kathleen Wynne says the province's health insurance plan will cover the cost of an expensive drug used to treat a rare form of cystic fibrosis after reaching a deal with the drug's U.S. manufacturer.

Twelve-year-old Madi Vanstone of Beeton, Ontario, has become the poster child for people who suffer from the rare disease and need the drug, Kalydeco, which costs $350,000 a year.

Madi had met with Wynne to ask that the province cover the cost of the drug, which she said made a huge improvement in the quality of her life.

Alberta led the negotiations with the drug manufacturer Vertex Pharmaceuticals a process that took months after the provinces complained they were being charged more than other countries for Kalydeco.

Wynne said during a campaign stop in Ottawa that the timing of the announcement was not related to the Ontario election, and says she's just glad Madi and others who need the drug will now have it covered.

It's estimated there are about 118 people across Canada that are treated with Kalydeco.

A small group of children had received the drug through clinical trials where Vertex Pharmaceuticals did cover the cost for several months "on compassionate grounds," but the company wouldn't say how many children were helped under that program.


Comments


NOTE: To post a comment in the new commenting system you must have an account with at least one of the following services: Disqus, Facebook, Twitter, Yahoo, OpenID. You may then login using your account credentials for that service. If you do not already have an account you may register a new profile with Disqus by first clicking the "Post as" button and then the link: "Don't have one? Register a new profile".

The The Battlefords News-Optimist welcomes your opinions and comments. We do not allow personal attacks, offensive language or unsubstantiated allegations. We reserve the right to edit comments for length, style, legality and taste and reproduce them in print, electronic or otherwise. For further information, please contact the editor or publisher, or see our Terms and Conditions.

blog comments powered by Disqus

Quick Vote

Survey results are meant for general information only, and are not based on recognised statistical methods.


Markets





LOG IN



Lost your password?